EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper

Emilio Perucca iD, Jacqueline A French iD, Ghaieb Aljandeel iD, Simona Balestrini iD, Patricia Braga iD, Jorge G Burneo iD, Augustina Charway Felli iD, J Helen Cross iD, Aristea S Galanopoulou iD, Satish Jain iD, Yuwu Jiang iD, Reetta Kälviäinen iD und 15 weitere

Epilepsia · 2024-03 · 65 (3) · 533-541

DOI: 10.1111/epi.17877 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 27.01.2024. Verfasst von Emilio Perucca und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The University of Melbourne (Austin Health), Heidelberg, Victoria, Australia. Hauptthemen laut MEDLINE: Epilepsy. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyHumansAnticonvulsantsBehavior TherapyConsensusCaregivers

Stichwörter der Autor:innen

antiepileptic drugsantiseizure medicationsrecommendationsterminology

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Medicine, The University of Melbourne (Austin Health), Heidelberg, Victoria, Australia.
  • Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
  • NYU Grossman School of Medicine and NYU Langone Health, New York, New York, USA.
  • Faculty of Epileptology, Iraqi Council for Medical Specializations, Medical City, Baghdad, Iraq.
  • Neuroscience Department, Meyer Children's Hospital, Florence, Italy.
  • University of Florence, Florence, Italy.

ORCID-Profile: Emilio Perucca, Jacqueline A French, Ghaieb Aljandeel, Simona Balestrini, Patricia Braga, Jorge G Burneo, Augustina Charway Felli, J Helen Cross, Aristea S Galanopoulou, Satish Jain, Yuwu Jiang, Reetta Kälviäinen, Shih Hui Lim, Kimford J Meador, Zarine Mogal, Rima Nabbout, Francesca Sofia, Ernest Somerville, Michael R Sperling, Chahnez Triki, Eugen Trinka, Matthew C Walker, Samuel Wiebe, Jo M Wilmshurst, Elaine Wirrell, Elza Márcia Yacubian, Jaideep Kapur

Förderung

  • NINDS NIH HHS

Zitieren

APA

Perucca, E., French, J. A., Aljandeel, G., Balestrini, S., Braga, P., Burneo, J. G., Felli, A. C., Cross, J. H., Galanopoulou, A. S., Jain, S., Jiang, Y., Kälviäinen, R., Lim, S. H., Meador, K. J., Mogal, Z., Nabbout, R., Sofia, F., Somerville, E., Sperling, M. R., …, & Kapur, J. (2024). Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia, 65(3), 533-541. https://doi.org/10.1111/epi.17877

Vancouver

Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, et al. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65(3):533-541. doi:10.1111/epi.17877

BibTeX
@article{Perucca2024,
  author = {Perucca, Emilio and French, Jacqueline A and Aljandeel, Ghaieb and Balestrini, Simona and Braga, Patricia and Burneo, Jorge G and Felli, Augustina Charway and Cross, J Helen and Galanopoulou, Aristea S and Jain, Satish and Jiang, Yuwu and Kälviäinen, Reetta and Lim, Shih Hui and Meador, Kimford J and Mogal, Zarine and Nabbout, Rima and Sofia, Francesca and Somerville, Ernest and Sperling, Michael R and Triki, Chahnez and Trinka, Eugen and Walker, Matthew C and Wiebe, Samuel and Wilmshurst, Jo M and Wirrell, Elaine and Yacubian, Elza Márcia and Kapur, Jaideep},
  title = {Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {3},
  pages = {533--541},
  doi = {10.1111/epi.17877}
}
Kostenlos starten →